Why the study?
Does an ultrathin strut bioresorbable polymer sirolimus-eluting stent reduce 12-month target lesion failure compared to a thin strut durable polymer everolimus-eluting stent in patients with acute coronary syndromes without STEMI?
Population
677 patients with acute coronary syndromes without ST-segment-elevation myocardial infarction from the…
Comparison
Ultrathin strut bioresorbable polymer… vs Thin strut durable polymer everolimus-eluting…
Design
RCT, 2:1 treatment, Blinded independent clinical events committee for outcome…
Follow-up
12 months
Authors
Loading...
In patients with ACS without STEMI, treatment with an ultrathin strut bioresorbable polymer sirolimus-eluting stent significantly reduced 12-month target lesion failure compared to a durable polymer everolimus-eluting stent, driven by lower periprocedural and spontaneous MI.
Does an ultrathin strut bioresorbable polymer sirolimus-eluting stent reduce 12-month target lesion failure compared to a thin strut durable polymer everolimus-eluting stent in patients with acute coronary syndromes without STEMI?
In patients with ACS without STEMI, treatment with an ultrathin strut bioresorbable polymer sirolimus-eluting stent significantly reduced 12-month target lesion failure compared to a durable polymer everolimus-eluting stent, driven by lower periprocedural and spontaneous MI.
Roguin et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: